LT3560924T - Imidazolonilchinolinai ir jų panaudojimas kaip atm kinazės inhibitorių - Google Patents

Imidazolonilchinolinai ir jų panaudojimas kaip atm kinazės inhibitorių

Info

Publication number: LT3560924T
Authority: LT; Lithuania
Prior art keywords: imidazolonylchinolines; kinase inhibitors; atm kinase; atm; inhibitors
Prior art date: 2015-04-02

Application number

LTEP19172903.7T

Other languages

English (en)

Inventor

Thomas Fuchss

Kai Schiemann

Original Assignee

Merck Patent Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2015-04-02

Filing date

2016-03-31

Publication date

2021-08-25

2016-03-31 Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh

2021-08-25 Publication of LT3560924T publication Critical patent/LT3560924T/lt

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Oncology (AREA)
Hematology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Plural Heterocyclic Compounds (AREA)

LTEP19172903.7T 2015-04-02 2016-03-31 Imidazolonilchinolinai ir jų panaudojimas kaip atm kinazės inhibitorių LT3560924T (lt)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
EP15000968		2015-04-02

Publications (1)

Publication Number	Publication Date
LT3560924T true LT3560924T (lt)	2021-08-25

Family

ID=52814780

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
LTEP16717560.3T LT3277681T (lt)	2015-04-02	2016-03-31	Imidazolonilchinolinai ir jų panaudojimas, kaip atm kinazės inhibitorių
LTEP19172903.7T LT3560924T (lt)	2015-04-02	2016-03-31	Imidazolonilchinolinai ir jų panaudojimas kaip atm kinazės inhibitorių

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
LTEP16717560.3T LT3277681T (lt)	2015-04-02	2016-03-31	Imidazolonilchinolinai ir jų panaudojimas, kaip atm kinazės inhibitorių

Country Status (23)

Country	Link
US (5)	US10457677B2 (lt)
EP (3)	EP3560924B1 (lt)
JP (2)	JP6791873B2 (lt)
KR (2)	KR20240044525A (lt)
CN (3)	CN111689963A (lt)
AU (4)	AU2016239270B2 (lt)
BR (1)	BR122019005502B1 (lt)
DK (2)	DK3560924T3 (lt)
ES (3)	ES2741853T3 (lt)
HR (2)	HRP20191396T1 (lt)
HU (2)	HUE045477T2 (lt)
IL (3)	IL254714B (lt)
LT (2)	LT3277681T (lt)
MX (2)	MX376947B (lt)
PL (2)	PL3277681T3 (lt)
PT (2)	PT3277681T (lt)
RS (2)	RS59139B1 (lt)
RU (1)	RU2743343C2 (lt)
SG (2)	SG10202002181UA (lt)
SI (2)	SI3277681T1 (lt)
TR (1)	TR201911244T4 (lt)
WO (1)	WO2016155884A1 (lt)
ZA (1)	ZA201707423B (lt)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DK3560924T3 (da) *	2015-04-02	2021-06-28	Merck Patent Gmbh	Imidazolonylquinoliner og deres anvendelse som atm-kinase-inhibitorer
GB201516504D0 (en)	2015-09-17	2015-11-04	Astrazeneca Ab	Imadazo(4,5-c)quinolin-2-one Compounds and their use in treating cancer
GB201519406D0 (en) *	2015-11-03	2015-12-16	Astrazeneca Ab	Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer
CN110312717B (zh) *	2017-02-27	2022-04-12	上海瑛派药业有限公司	取代的稠合杂芳三环化合物作为激酶抑制剂及其应用
JOP20190209A1 (ar) *	2017-03-16	2019-09-12	Astrazeneca Ab	مركبات إيميدازو [ 4، 5-c ] كينولين-2-أون ديوترومية واستخدامها في علاج السرطان
KR20200109345A (ko)	2018-01-12	2020-09-22	프로린크스 엘엘시	상승적 암 치료
MX2020009478A (es) *	2018-03-14	2020-10-22	Merck Patent Gmbh	Compuestos y sus usos para tratar tumores en un paciente.
BR112020018006A2 (pt)	2018-04-12	2021-01-12	Bayer Aktiengesellschaft	Derivados de n-(ciclopropilmetil)-5-(metilsulfonil)-n-{1-[1-(pirimidin-2-il)-1h-1,2,4-triazol-5-il]etil}benzamida e os derivados correspondentes de piridina-carboxamida como pesticidas
WO2019201283A1 (en) *	2018-04-20	2019-10-24	Xrad Therapeutics, Inc.	Dual atm and dna-pk inhibitors for use in anti-tumor therapy
CN110386932A (zh) *	2018-04-20	2019-10-29	艾科思莱德制药公司	用于抗肿瘤疗法中的双重atm和dna-pk抑制剂
GB201814487D0 (en) *	2018-09-06	2018-10-24	Cycle Pharmaceuticals Ltd	Cancer
CN109045042A (zh) *	2018-09-21	2018-12-21	上海交通大学医学院附属上海儿童医学中心	Atm抑制剂在制备抑制急性淋巴细胞性白血病复发的药物中的应用
JP6997358B2 (ja) *	2018-09-30	2022-01-17	メッドシャインディスカバリーインコーポレイテッド	キノリノピロリジン－２－オン系誘導化合物及びその使用
SG11202110480YA (en)	2019-03-27	2021-10-28	Merck Patent Gmbh	Imidazolonylquinoline compounds and therapeutic uses thereof
EP4003345B1 (en) *	2019-07-30	2024-12-04	XRad Therapeutics, Inc.	Dual atm and dna-pk inhibitors for use in anti-tumor therapy
CA3154413A1 (en) *	2019-11-01	2021-05-06	Yan Lan	Combined inhibition of pd-1, tgf.beta. and atm together with radiotherapy for the treatment of cancer
ES3023544T3 (en)	2019-12-04	2025-06-02	Chdi Foundation Inc	Atm kinase inhibitors and compositions and methods of use thereof
WO2021139814A1 (zh) *	2020-01-09	2021-07-15	南京明德新药研发有限公司	喹啉并咪唑类化合物及其应用
CN115380031A (zh) *	2020-03-30	2022-11-22	南京明德新药研发有限公司	作为atm抑制剂的喹啉并吡咯烷-2-酮类化合物的晶型及其应用
WO2021254982A1 (en) *	2020-06-18	2021-12-23	Merck Patent Gmbh	Compounds for the treatment of viral infections
EP4171651A1 (en)	2020-06-24	2023-05-03	AstraZeneca UK Limited	Combination of antibody-drug conjugate and atm inhibitor
EP4213803A1 (en)	2020-09-18	2023-07-26	Merck Patent GmbH	Pharmaceutical preparation
JP7669473B2 (ja) *	2020-09-21	2025-04-28	ウェイジョン	血液脳関門透過能力を有する置換１－（３，３－ジフルオロピペリジン－４－イル）－イミダゾ［４，５－ｃ］キノリン－２－オン化合物
EP3992191A1 (en)	2020-11-03	2022-05-04	Deutsches Krebsforschungszentrum	Imidazo[4,5-c]quinoline compounds and their use as atm kinase inhibitors
CN115232122B (zh) *	2021-04-23	2024-05-31	石药集团中奇制药技术（石家庄）有限公司	炔类化合物及其制备和应用
CN115716829B (zh) *	2022-11-13	2024-05-31	药康众拓(江苏)医药科技有限公司	一种喹啉并咪唑酮联氘代吡唑类化合物及其应用
JP2025540024A (ja) *	2022-11-23	2025-12-11	フォワードセラピューティクス，インコーポレイテッド	ＴＮＦ－α活性の調節因子
WO2025157979A1 (en)	2024-01-26	2025-07-31	Merck Patent Gmbh	Synthesis route for preparing 8-(1,3-dimethyl-1h-pyrazol-4-yl)-1-(sa)-(3-fluoro-5-methoxy-pyridin-4-yl)-7-methoxy-3-methyl-1,3-dihydro-imidazo[4,5-c]quinolin-2-one
WO2025212627A1 (en)	2024-04-03	2025-10-09	Forward Therapeutics, Inc.	Modulators of tnf-alpha activity
WO2025217307A1 (en)	2024-04-09	2025-10-16	Revolution Medicines, Inc.	Methods for predicting response to a ras(on) inhibitor and combination therapies
WO2025240847A1 (en)	2024-05-17	2025-11-20	Revolution Medicines, Inc.	Ras inhibitors
WO2025255438A1 (en)	2024-06-07	2025-12-11	Revolution Medicines, Inc.	Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en)	2024-06-21	2025-12-26	Revolution Medicines, Inc.	Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en)	2024-06-28	2026-01-02	Revolution Medicines, Inc.	Ras inhibitors
WO2026015796A1 (en)	2024-07-12	2026-01-15	Revolution Medicines, Inc.	Methods of treating a ras related disease or disorder
WO2026015790A1 (en)	2024-07-12	2026-01-15	Revolution Medicines, Inc.	Methods of treating a ras related disease or disorder
WO2026015825A1 (en)	2024-07-12	2026-01-15	Revolution Medicines, Inc.	Use of ras inhibitor for treating pancreatic cancer
WO2026015801A1 (en)	2024-07-12	2026-01-15	Revolution Medicines, Inc.	Methods of treating a ras related disease or disorder

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6221335B1 (en) *	1994-03-25	2001-04-24	Isotechnika, Inc.	Method of using deuterated calcium channel blockers
PT1104760E (pt) *	1999-12-03	2003-06-30	Pfizer Prod Inc	Compostos de sulfamoil-heteroarilpirazole como agentes analgesicos e anti-inflamatorios
GB0211649D0 (en)	2002-05-21	2002-07-03	Novartis Ag	Organic compounds
AU2006226412A1 (en)	2005-03-21	2006-09-28	Ferrer Internacional, S. A.	Method for making 1-substituted 1H-imidazo(4,5-c)quinolin-4-amine compounds and intermediates therefor
GB0510390D0 (en)	2005-05-20	2005-06-29	Novartis Ag	Organic compounds
EP1934201A1 (en) *	2005-10-06	2008-06-25	Auspex Pharmaceuticals Inc.	Deuterated inhibitors of gastric h+, k+-atpase with enhanced therapeutic properties
US7750168B2 (en) *	2006-02-10	2010-07-06	Sigma-Aldrich Co.	Stabilized deuteroborane-tetrahydrofuran complex
CN101616672A (zh)	2007-02-20	2009-12-30	诺瓦提斯公司	作为脂质激酶和mTOR双重抑制剂的咪唑并喹啉类
KR20100126553A (ko)	2008-03-26	2010-12-01	노파르티스 아게	Ｖｅｇｆ-유도성 혈관신생 과정의 유력한 조절제로서의 이미다조퀴놀린 및 피리미딘 유도체
PE20110223A1 (es)	2008-06-10	2011-05-07	Abbvie Inc	DERIVADOS DE PIRROLO[2,3-e][1,2,4]TRIAZOLO[4,3-a]PIRAZIN, COMO INHIBIDORES DE QUINASA
MX340304B (es)	2008-10-01	2016-07-05	Novartis Ag *	Antagonismo de smoothened para el tratamiento de los trastornos relacionados con la senda de hedgehog.
WO2010139747A1 (en)	2009-06-04	2010-12-09	Novartis Ag	1H-IMIDAZO[4, 5-c]QUINOLINONE COMPOUNDS, USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES
AU2010255727B2 (en) *	2009-06-04	2013-02-28	Novartis Ag	1H-imidazo[4,5-c]quinolinone derivatives
GB0919423D0 (en) *	2009-11-05	2009-12-23	Glaxosmithkline Llc	Novel compounds
US9126952B2 (en) *	2010-03-16	2015-09-08	Merck Patent Gmbh	Morpholinylquinazolines
PE20130376A1 (es) *	2010-06-28	2013-03-30	Merck Patent Gmbh	[1,8]naftiridinas sustituidas por 2,4-diarilo como inhibidores de quinasas para uso contra el cancer
CN102372711B (zh)	2010-08-18	2014-09-17	山东轩竹医药科技有限公司	咪唑并喹啉类PI3K和mTOR双重抑制剂
DE102010035744A1 (de)	2010-08-28	2012-03-01	Merck Patent Gmbh	Imidazolonylchinoline
CN102399218A (zh)	2010-09-16	2012-04-04	和记黄埔医药（上海）有限公司	一类并合三杂环及其作为pi3k抑制剂的用途
RU2013130224A (ru)	2010-12-03	2015-01-10	Новартис Аг	Фармацевтические композиции
CN103012398B (zh)	2011-09-19	2015-10-14	上海恒瑞医药有限公司	咪唑并喹啉类衍生物及其可药用盐、其制备方法及其在医药上的应用
US9879003B2 (en)	2012-04-11	2018-01-30	Dana-Farber Cancer Institute, Inc.	Host targeted inhibitors of dengue virus and other viruses
JP2015518888A (ja)	2012-06-06	2015-07-06	ノバルティスアーゲー	腫瘍疾患を治療するための１７−アルファ−ヒドロキシラーゼ（ｃ１７，２０−リアーゼ）インヒビターと特定のｐｉ−３ｋインヒビターとの組み合わせ
NO2714752T3 (lt) *	2014-05-08	2018-04-21
DK3560924T3 (da)	2015-04-02	2021-06-28	Merck Patent Gmbh	Imidazolonylquinoliner og deres anvendelse som atm-kinase-inhibitorer

2016
- 2016-03-31 DK DK19172903.7T patent/DK3560924T3/da active
- 2016-03-31 CN CN202010644289.6A patent/CN111689963A/zh active Pending
- 2016-03-31 BR BR122019005502-5A patent/BR122019005502B1/pt active IP Right Grant
- 2016-03-31 ES ES16717560T patent/ES2741853T3/es active Active
- 2016-03-31 RS RS20190993A patent/RS59139B1/sr unknown
- 2016-03-31 MX MX2017012613A patent/MX376947B/es active IP Right Grant
- 2016-03-31 EP EP19172903.7A patent/EP3560924B1/de active Active
- 2016-03-31 LT LTEP16717560.3T patent/LT3277681T/lt unknown
- 2016-03-31 RS RS20210817A patent/RS62082B1/sr unknown
- 2016-03-31 PL PL16717560T patent/PL3277681T3/pl unknown
- 2016-03-31 PT PT16717560T patent/PT3277681T/pt unknown
- 2016-03-31 EP EP21165573.3A patent/EP3868761B1/de active Active
- 2016-03-31 CN CN201680031887.8A patent/CN107889488B/zh active Active
- 2016-03-31 AU AU2016239270A patent/AU2016239270B2/en active Active
- 2016-03-31 DK DK16717560.3T patent/DK3277681T3/da active
- 2016-03-31 KR KR1020247009513A patent/KR20240044525A/ko active Pending
- 2016-03-31 KR KR1020177031770A patent/KR102652052B1/ko active Active
- 2016-03-31 HU HUE16717560A patent/HUE045477T2/hu unknown
- 2016-03-31 SI SI201630345T patent/SI3277681T1/sl unknown
- 2016-03-31 PT PT191729037T patent/PT3560924T/pt unknown
- 2016-03-31 PL PL19172903T patent/PL3560924T3/pl unknown
- 2016-03-31 SG SG10202002181UA patent/SG10202002181UA/en unknown
- 2016-03-31 CN CN202010644109.4A patent/CN111747952A/zh active Pending
- 2016-03-31 HU HUE19172903A patent/HUE054745T2/hu unknown
- 2016-03-31 US US15/563,680 patent/US10457677B2/en active Active
- 2016-03-31 LT LTEP19172903.7T patent/LT3560924T/lt unknown
- 2016-03-31 EP EP16717560.3A patent/EP3277681B1/de active Active
- 2016-03-31 ES ES21165573T patent/ES2946507T3/es active Active
- 2016-03-31 TR TR2019/11244T patent/TR201911244T4/tr unknown
- 2016-03-31 WO PCT/EP2016/000542 patent/WO2016155884A1/de not_active Ceased
- 2016-03-31 SG SG11201708065QA patent/SG11201708065QA/en unknown
- 2016-03-31 JP JP2017551589A patent/JP6791873B2/ja active Active
- 2016-03-31 MX MX2020011558A patent/MX390537B/es unknown
- 2016-03-31 ES ES19172903T patent/ES2880626T3/es active Active
- 2016-03-31 RU RU2017138100A patent/RU2743343C2/ru active
- 2016-03-31 SI SI201631240T patent/SI3560924T1/sl unknown
- 2016-03-31 HR HRP20191396 patent/HRP20191396T1/hr unknown
2017
- 2017-09-26 IL IL254714A patent/IL254714B/en active IP Right Grant
- 2017-11-01 ZA ZA2017/07423A patent/ZA201707423B/en unknown
2019
- 2019-03-14 US US16/353,559 patent/US10745399B2/en active Active
- 2019-12-17 IL IL271494A patent/IL271494B/en active IP Right Grant
2020
- 2020-06-24 US US16/910,438 patent/US10975075B2/en active Active
- 2020-06-25 AU AU2020204241A patent/AU2020204241B2/en active Active
- 2020-11-05 JP JP2020185129A patent/JP7111790B2/ja active Active
2021
- 2021-03-17 US US17/204,619 patent/US11608338B2/en active Active
- 2021-04-22 IL IL282584A patent/IL282584B/en unknown
- 2021-06-23 HR HRP20210981TT patent/HRP20210981T1/hr unknown
2022
- 2022-10-21 AU AU2022256215A patent/AU2022256215A1/en not_active Abandoned
2023
- 2023-03-01 US US18/116,094 patent/US20230203034A1/en active Pending
2025
- 2025-01-20 AU AU2025200385A patent/AU2025200385A1/en active Pending

Also Published As

Publication number	Publication date
IL271494A (en)	2020-02-27
JP2021046403A (ja)	2021-03-25
SG11201708065QA (en)	2017-10-30
IL271494B (en)	2021-05-31
MX2020011558A (es)	2022-03-09
US20210198257A1 (en)	2021-07-01
KR20240044525A (ko)	2024-04-04
EP3560924B1 (de)	2021-03-31
US10975075B2 (en)	2021-04-13
EP3560924A1 (de)	2019-10-30
NZ736641A (en)	2024-09-27
AU2020204241A1 (en)	2020-07-16
ES2741853T3 (es)	2020-02-12
PT3277681T (pt)	2019-08-20
US11608338B2 (en)	2023-03-21
EP3868761A1 (de)	2021-08-25
MX2017012613A (es)	2018-01-24
US10745399B2 (en)	2020-08-18
JP6791873B2 (ja)	2020-11-25
PL3560924T3 (pl)	2021-10-11
EP3277681B1 (de)	2019-05-08
PT3560924T (pt)	2021-07-02
EP3277681A1 (de)	2018-02-07
CN111747952A (zh)	2020-10-09
DK3277681T3 (da)	2019-07-29
ES2880626T3 (es)	2021-11-25
US20200325137A1 (en)	2020-10-15
JP2018510191A (ja)	2018-04-12
MX390537B (es)	2025-03-20
SI3277681T1 (sl)	2019-09-30
CN107889488A (zh)	2018-04-06
RS59139B1 (sr)	2019-09-30
CN111689963A (zh)	2020-09-22
ZA201707423B (en)	2021-05-26
IL282584A (en)	2021-06-30
CN107889488B (zh)	2020-08-11
SI3560924T1 (sl)	2021-08-31
HRP20210981T1 (hr)	2021-09-17
AU2016239270B2 (en)	2020-03-26
ES2946507T3 (es)	2023-07-20
MX376947B (es)	2025-03-07
AU2025200385A1 (en)	2025-02-13
KR20170132323A (ko)	2017-12-01
RU2743343C2 (ru)	2021-02-17
US20230203034A1 (en)	2023-06-29
PL3277681T3 (pl)	2019-10-31
NZ774407A (en)	2024-09-27
TR201911244T4 (tr)	2019-08-21
US20180072715A1 (en)	2018-03-15
EP3868761B1 (de)	2023-03-01
RU2017138100A (ru)	2019-05-08
IL282584B (en)	2021-12-01
US20190211013A1 (en)	2019-07-11
RS62082B1 (sr)	2021-08-31
AU2020204241B2 (en)	2022-11-17
LT3277681T (lt)	2019-08-12
SG10202002181UA (en)	2020-05-28
CA2981365A1 (en)	2016-10-06
BR122019005502B1 (pt)	2024-02-27
AU2022256215A1 (en)	2022-11-24
HUE054745T2 (hu)	2021-09-28
KR102652052B1 (ko)	2024-03-27
BR112017020941A2 (pt)	2018-07-10
HUE045477T2 (hu)	2019-12-30
IL254714A0 (en)	2017-11-30
DK3560924T3 (da)	2021-06-28
JP7111790B2 (ja)	2022-08-02
WO2016155884A1 (de)	2016-10-06
RU2017138100A3 (lt)	2019-10-04
HRP20191396T1 (hr)	2019-11-01
IL254714B (en)	2020-01-30
US10457677B2 (en)	2019-10-29
AU2016239270A1 (en)	2017-11-16

Publication	Publication Date	Title
LT3560924T (lt)	2021-08-25	Imidazolonilchinolinai ir jų panaudojimas kaip atm kinazės inhibitorių
IL280863A (en)	2021-04-29	Autotaxin inhibitors and uses thereof
LT3317284T (lt)	2020-01-27	Benzoksazepino oksazolidinono junginiai ir jų naudojimo būdai
DK3303334T3 (da)	2021-06-28	Tyrosinkinasehæmmere
LT3193611T (lt)	2021-08-25	Mk2 inhibitoriai ir jų panaudojimas
HRP20190039T1 (hr)	2019-03-08	Inhibitori ciklin-ovisne kinaze 7 (cdk7)
LT3221306T (lt)	2020-03-10	Heteroarilo junginiai, kaip irak inhibitoriai ir jų panaudojimas
LT3177608T (lt)	2019-10-10	Proteinkinazės c inhibitoriai ir jų naudojimo būdai
GB201605126D0 (en)	2016-05-11	Inhibitors and their uses
MA40933A (fr)	2017-09-19	Difluorométhyl-aminopyridines et difluorométhyl-aminopyrimidines
IL259150B (en)	2021-05-31	Pyrimidine derivative and use thereof
LT3102555T (lt)	2021-06-25	Junginių kompozicijos ir jų panaudojimas
DK3015526T3 (da)	2021-01-18	Hydrofluorolefinbaseret sammensætning og anvendelse deraf
DK3161139T3 (da)	2020-10-19	Tlr-4-specifikke aptamerer og anvendelser heraf
HRP20190432T1 (hr)	2019-04-19	Spojevi pladienolid piridina i postupci uporabe
LT3337506T (lt)	2021-10-11	Deriniai ir jų panaudojimas
IL254916B (en)	2021-10-31	Inhibitors and their uses
IL251077A0 (en)	2017-04-30	Integrin inhibitors and their use
DE112015003841A5 (de)	2017-07-06	Di- und triphosphat-propharmaka
LT3247711T (lt)	2022-05-25	Naujos scy-078 druskos ir polimorfai
MA44607A (fr)	2021-05-19	Inhibiteurs de kinase
IL251078B (en)	2021-05-31	Integrin inhibitors and their use
DK3180335T3 (da)	2021-08-09	Cytokrom-p450-inhibitorer og anvendelser deraf
PL2988083T3 (pl)	2017-12-29	Szafa o regulowanej temperaturze
FI10550U1 (fi)	2014-07-18	Kylmäkaluste